Filing Flows › Comparisons › BGLC vs SERA
BioNexus Gene Lab vs Sera Prognostics: BGLC and SERA compared
BioNexus Gene Lab is the larger company: $76K of revenue in its latest quarter (Q2 2026) against $42K for Sera Prognostics (Q3 2026). Sera Prognostics is growing faster (+162% against -97% a year earlier).
Where the money goes: BGLC and SERA
BioNexus Gene Lab (BGLC) · Q2 2026
BioNexus Gene Lab, Q2 2026: revenue $76K (-97% year over year), operating margin -370.8%, net loss $286K, operating cash flow −$422K. The chart follows the revenue to costs, profit and cash.
Sera Prognostics (SERA) · Q3 2026
Sera Prognostics, Q3 2026: revenue $42K (+162% year over year), net loss $8.1M, operating cash flow −$7.3M. The chart follows the revenue to costs, profit and cash.
| BioNexus Gene Lab (BGLC) | Sera Prognostics (SERA) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $76K | $42K |
| Revenue growth, Y/Y | -97% | +162% |
| Operating margin | -370.8% | n/m |
| Net earnings | −$286K | −$8.1M |
| Net margin | -376.1% | — |
| Operating cash flow | −$422K | −$7.3M |
Questions
Which is bigger, BioNexus Gene Lab or Sera Prognostics?
BioNexus Gene Lab is the larger company: $76K of revenue in its latest quarter (Q2 2026) against $42K for Sera Prognostics (Q3 2026).
Is BioNexus Gene Lab or Sera Prognostics growing faster?
Sera Prognostics is growing faster (+162% against -97% a year earlier).
More: BioNexus Gene Lab earnings · how BioNexus Gene Lab makes money · Sera Prognostics earnings · how Sera Prognostics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.